Starting dose side effects are milder than therapeutic dose side effects
A gradual tapering protocol reduces these effects
Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off
By watching trends and collecting more information, healthcare systems can better understand how tirzepatide affects people in the real worldand ensure it is used as safely as possible
For this reason, frozen tirzepatide should not be used under any condition
Clinical trial data provides useful benchmarks, but your individual response matters most